Toronto, Ontario - TheNewswire - October 3, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce the appointment of Mr. Jimmy Jeon as Chief Financial Officer (“CFO”) of the Company. Mr. Jeon replaces Mr. Victor Hugo, who has served as CFO since June 2020. The Company wishes to thank Mr. Hugo for fulfilling that role and to express its appreciation for his service.
Mr. Jeon currently works as a Senior Financial Analysist at Marrelli Support Services Inc. where he provides CFO, accounting, regulatory compliance, and management advisory services to numerous public trading companies on the TSX, TSX Venture Exchange and other Canadian and U.S. exchanges. Mr. Jeon is a CPA and holds a Bachelor of Business Administration and Graduate Diploma in Accounting from Wilfrid Laurier University. Mr. Jeon has over 6 years’ experience in various sectors, with responsibility for accounting, budgeting, financial reporting and disclosures.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Jonathan Robinson
This email address is being protected from spambots. You need JavaScript enabled to view it.
(416)-669-1001
Dr. Alvira Macanovic
President & CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
(416) 848-4156
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Last Trade: | C$0.10 |
Daily Change: | 0.01 11.11 |
Daily Volume: | 239,156 |
Market Cap: | C$15.970M |
December 18, 2024 December 17, 2024 November 14, 2024 November 06, 2024 October 24, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB